Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Published on May 16, 2014 at 7:36 AM · No Comments

Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain "PVCT" but it will withdraw its shares from quotation on the OTCQB concurrent with listing its shares on the NYSE MKT.

Dr. Craig Dees, PhD, CEO of Provectus said, "Listing on the NYSE MKT is a huge milestone for Provectus Biopharmaceuticals, and I take a great deal of personal satisfaction from this news. I believe that this will enhance our shareholder value as well as broaden our shareholder base and heighten our corporate profile in the capital markets."

NYSE MKT is a fully integrated trading venue within the NYSE Euronext community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE Euronext community.

"We welcome Provectus to the NYSE community and look forward to a strong partnership with the Company and its shareholders," said Scott Cutler, Executive Vice President and Head of Global Listings at NYSE Euronext. "Provectus will join other pharmaceutical companies that benefit from NYSE's trusted and reliable platform to raise capital."

Source:

Provectus Biopharmaceuticals, Inc.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients